| Literature DB >> 32201766 |
Nadjet Rezki1,2, Fawzia Faleh Al-Blewi1, Salsabeel A Al-Sodies1, Asaad Khalid Alnuzha1, Mouslim Messali1, Imran Ali1,3, Mohamed Reda Aouad1,2.
Abstract
Newer imidazolium ionic liquid (IL) halides 4a-f appending variety of fluorinated phenylacetamide side chains were designed and synthesized through quaternization of 1-methyl and/or 1,2-dimethylimidazole with appropriate 2-chloro-N-(fluorinatedphenyl)acetamides. The resulting ILs were converted to their respective ionic liquid analogues carrying fluorinated counteranions (PF6 -, BF4 -, and/or CF3COO-) 5a-r. All newly synthesized ILs were fully characterized using several spectroscopic experiments such as 1H, 13C, 11B, 19F, 31P NMR, and mass analysis. The synthesized ionic liquids were investigated for their DNA binding and anticancer activities. The obtained DNA binding constants ranged from 1.444 × 105 to 3.518 × 105, indicating a reasonably good binding affinity. The percentage of anticancer activities ranged from 48 to 59 with H-1229 cell line, showing quite good anticancer potential. The modeling studies indicated the interactions of the reported molecules with DNA via hydrogen bonds. These were in agreement with those of DNA binding and anticancer results. Briefly, the designed ionic liquids may be used as good anticancer candidates for treating human cancer.Entities:
Year: 2020 PMID: 32201766 PMCID: PMC7081306 DOI: 10.1021/acsomega.9b03468
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Scheme 1Synthesis of Ionic Liquids Bearing Imidazole Ring and Fluorinated Phenylacetamide Linkages 4a–f and 5a–r
Physical and Analytical Data for the Imidazolium IL Halides 4a–f
Physical and Analytical Data of the Imidazolium ILs Carrying Fluorinated Counteranions 5a–r
Figure 1DNA binding study of compound 4a.
UV–Vis Data for Compounds 4a–f and 5a–ra
| comp. no. | Δλmax (nm) | % hypochromism | |||
|---|---|---|---|---|---|
| 1.311 | 1.123 | 0.188 | 14 | 1.825 × 105 | |
| 2.068 | 2.154 | 0.086 | 4 | 2.124 × 105 | |
| 1.594 | 1.422 | 0.172 | 10.7 | 2.547 × 105 | |
| 1.384 | 1.204 | 0.18 | 13 | 2.568 × 105 | |
| 0.553 | 0.503 | 0.05 | 9 | 1.5245 × 105 | |
| 0.029 | 0.025 | 0.004 | 13.7 | 2.356 × 105 | |
| 1.359 | 1.145 | 0.214 | 15.7 | 2.739 × 105 | |
| 0.13 | 0.113 | 0.017 | 13 | 1.832 × 105 | |
| 0.120 | 0.132 | 0.012 | 1 | 1.506 × 105 | |
| 0.218 | 0.226 | 0.008 | 3.6 | 1.444 × 105 | |
| 0.028 | 0.029 | 0.001 | 3.5 | 5.566 × 104 | |
| 2.350 | 2.261 | 0.089 | 3.7 | 1.693 × 105 | |
| 1.520 | 1.424 | 0.096 | 6 | 2.5 × 105 | |
| 1.745 | 1.549 | 0.196 | 11 | 1.928 × 105 | |
| 0.987 | 0.882 | 0.105 | 10 | 2.716 × 105 | |
| 0.023 | 0.026 | 0.003 | 13 | 2.40 × 105 | |
| 0.997 | 0.945 | 0.052 | 5 | 1.829 × 105 | |
| 1.265 | 1.153 | 0.112 | 8.8 | 1.935 × 105 | |
| 0.449 | 0.469 | 0.02 | 4 | 1.802 × 105 | |
| 0.591 | 0.523 | 0.068 | 11.5 | 4.543 × 104 | |
| 1.126 | 1.074 | 0.052 | 4.6 | 3.518 × 105 | |
| 0.145 | 0.150 | 0.005 | 3 | 2.303 × 105 | |
| 0.141 | 0.151 | 0.01 | 7 | 3.109 × 105 | |
| 1.549 | 1.305 | 0.244 | 15.7 | 3.032 × 105 |
% Hypochromism (H%) = [change in λmax/Af] × 100, where Af and Ab are the absorbances of free and bound compounds, respectively, Kb = binding constants, λf = λmax (free), λb = λmax (bound to DNA).
Figure 2Anticancer profiles of the reported molecules with H-1229 cell line.
Simulation Studies Results of the Reported Compounds with DNA
| comp. no. | no. of H bonds | bond length (Å) | affinity in (kcal/mol) | hydrophobic interaction |
|---|---|---|---|---|
| 1 | .263/A/DG′10/O6 & ‘H’ of −CONH- gp. (2.2) | –4.4 | C1::dc15&dc9, C2::dc9, C3::dt8&dc9, C4::dc9, C5::O6, C8::dc15&dg14, C10::dg14&dc15, C12::O, N3::O6 | |
| 2 | .263/A/DG′10/O6 & ‘H’ of −CONH- gp. (2.4) | –4.3 | C2::dg14&O6, C4::dg14, C5::O6, C7::dc15, C8::dc15, C9::dc15, C10::dg14&dc15, C13::O6, N2::dc15, O::dc9 | |
| .127/A/DC′9/N4 & ‘O’ of −CONH- gp. (3.4) | ||||
| 3 | .263/A/DG′10/O6 & ‘H’ of −CONH- gp. (2.3) | –4.4 | C2::dt8&dc9, C3::dc9, C5::O6, C6::dg14, C7::dg14, C8::dc15, C10::dc15, C12::dc15&O6, N2::dc15 | |
| .263/A/DG′10/O6 & ‘O’ of −CONH- gp. (3.3) | ||||
| .218/B/DG′14/N7 & ‘O’ of −CONH- (3.4) | ||||
| 1 | .263/A/DG′10/O6 & ‘H’ of −CONH- gp. (2.5) | –3.9 | C3::dc9, C4::dt8&dc9, C6::O6, C7::dg14, C8::dg14, C11::dc9&O6, C13::O6, N3::dg10&O6 | |
| 1 | .263/A/DG′10/O6 & ‘H’ of −CONH- gp. (2.1) | –4.4 | C1::dc9&dc15, C3::O6, C6::dg14&dc15, C8::dg14&dc15, C9::dc9&dt8, C10::dt8, C12::O6 | |
| 2 | .263/A/DG′10/O6 & ‘H’ of −CONH- gp. (2.6) | –4.3 | C1::dg14&O6, C4::O6, C5::dc15, C6::dc15, C7::dc15, C8::dc15&dg14, C10::dg14, C13::dc9&O6, N2::dc15 | |
| .127/A/DC′9/N4 & ‘O’ of −CONH- gp. (3.4) |
Figure 3Docking model of compound 4a with DNA.